Avenue Therapeutics, Inc.
ATXI
$0.39
-$0.09-18.29%
OTC PK
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -32.30% | -34.02% | -37.41% | 13.53% | -9.32% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -40.16% | -77.06% | -60.80% | -48.61% | -24.68% |
| Operating Income | 40.16% | 77.06% | 110.52% | 48.61% | 24.68% |
| Income Before Tax | 53.43% | 77.58% | 112.18% | 57.28% | -352.67% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 53.43% | 77.58% | 112.18% | 57.28% | -352.67% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 13.33% | -18.18% | -33.33% | -33.33% | -34.78% |
| Net Income | 54.08% | 77.80% | 112.44% | 57.33% | -341.25% |
| EBIT | 40.16% | 77.06% | 110.52% | 48.61% | 24.68% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 72.66% | 88.84% | -92.76% | 95.95% | -135.50% |
| Normalized Basic EPS | 65.03% | 88.91% | 104.43% | 91.93% | -134.54% |
| EPS Diluted | 72.66% | 88.84% | -92.76% | 95.95% | -135.50% |
| Normalized Diluted EPS | 65.03% | 88.91% | 104.43% | 91.93% | -134.54% |
| Average Basic Shares Outstanding | 68.00% | 98.95% | 184.81% | 428.61% | 579.81% |
| Average Diluted Shares Outstanding | 68.00% | 98.95% | 184.81% | 428.61% | 579.81% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |